Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The emergence of untreatable strains of typhoid threatens a new global health emergency that requires urgent collective action, argue experts from the Oxford Martin School in the journal Clinical Infectious Diseases today.

Photo: Bill & Melinda Gates Foundation/Sam Reinders

Typhoid still affects at least 11 million people every year, with the real figure potentially as high as 18 million. On the eve of the rollout of a new typhoid conjugate vaccine (TCV), the researchers are calling for global health institutions to dedicate new resources to tackling typhoid, which they say has become a neglected disease of poorer countries following its elimination in many high-income countries. Rising antimicrobial resistance and the ongoing outbreak of extensively drug-resistant (XDR) typhoid in Pakistan should be a wake-up call to the international community, they say.

New vaccines offer hope for typhoid control, but one intervention alone will be insufficient for eliminating the disease. Analysing the past and present of typhoid control, the researchers – including historians, immunologists and social scientists – identify a range of actions key to the strategic elimination of typhoid globally.

Their findings include:

  • Typhoid is still a major global health issue but is largely unrecognised, due to factors including poor surveillance and the complex dynamics of the disease, including new drug-resistant strains.
  • The availability of cheap credit and sustainable financing schemes for affordable water and sanitary systems at the municipal level have an important role to play in typhoid control (as seen in the elimination of typhoid in the UK and US).
  • There is a need to pair top-down nation state-led programmes with a greater emphasis on bottom-up approaches, enabling municipal coalitions to develop, adapt, and own locally-tailored water, sanitation, hygiene and health systems.
  • A lack of international financing has stalled the spread of sanitary and health infrastructures that played a key role in eliminating typhoid in high-income countries. Instead, the focus in wealthier, typhoid-free countries has been on protecting travellers and preventing typhoid from crossing borders.
  • Fragmented global action on typhoid and intensive use of antibiotics to compensate for weak water and healthcare systems have fuelled antimicrobial resistance in low- and middle-income countries.
  • Progress on typhoid control will depend on support for independent research and policy decisions within endemic countries to improve water quality.
  • The recent advent of a new generation of typhoid conjugate vaccines, which can also be used for children under two years of age, can play an important role until clean water and sanitation are in place for those at greatest risk.

The research was led by Dr Claas Kirchhelle, Dr Samantha Vanderslott and Professor Andrew Pollard, as part of their work on the Oxford Martin Programme on Collective Responsibility for Infectious Disease.

Dr Kirchhelle, of the Wellcome Unit for History of Medicine at the University of Oxford, said: “Popular notions of typhoid as a disease of the past are a myth. For poorer countries, the spectre of typhoid has never gone away. Over the last decades, international neglect, lacking sanitary infrastructures and vaccine programmes, and compensatory reliance on antibiotics have resulted in a situation where typhoid is increasingly difficult to treat. The current resurgence of extensively drug-resistant (XDR) typhoid bears the biosocial footprint of more than half a century of antibiotic-intensive international neglect.”

Dr Vanderslott, of the Oxford Vaccine Group, added: “The emergence of untreatable strains needs to be taken far more seriously. Top-down interventions such as vaccination programmes need to be combined with flexible credit to empower local communities, so that they can implement essential infrastructure such as waste disposal, sanitation and clean water systems.”

Progress on the new typhoid vaccine was accelerated by a pioneering use of a controlled human infection model (CHIM) in Oxford - which enabled scientists to test a number of candidate vaccines.

Professor Andrew Pollard, who leads the Oxford Vaccine Group, said: “The escalating problem of antimicrobial resistance means we need urgently to deploy new interventions to tackle typhoid. The availability and funding of new effective typhoid vaccines give us a critical tool for strengthening global control of typhoid, with the potential to protect vulnerable populations from this disease.”


Read the supplement in in Clinical Infectious Diseases

Making a Difference? The past, present and future of typhoid control


Similar stories

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Promising Marburg vaccine yet to be tested on humans due to lack of funding

Oxford University’s Professor Teresa Lambe, the designer of the vaccine, fears Marburg disease is ‘now being seen in places where it’s never been seen before’

Early life infection increases sensitivity to pain in newborn babies

Researchers from Oxford’s Department of Paediatrics have discovered that infection can increase a baby’s sensitivity to pain, which may last longer than the infection.

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.